IN8bio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INAB research report →
Companyin8bio.com
IN8bio, Inc. , a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation.
- CEO
- Tai-Wei
- IPO
- 2021
- Employees
- 18
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $7.28M
- P/E
- -0.36
- P/S
- 0.00
- P/B
- 0.30
- EV/EBITDA
- 0.72
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -96.39%
- ROIC
- -76.21%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-19,440,000 · 36.13%
- EPS
- $-4.44 · -678.95%
- Op Income
- $-19,861,000
- FCF YoY
- 47.59%
Performance & Tape
- 52W High
- $5.61
- 52W Low
- $1.17
- 50D MA
- $1.57
- 200D MA
- $1.90
- Beta
- 0.08
- Avg Volume
- 61.94K
Get TickerSpark's AI analysis on INAB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 9, 26 | Ho William Tai-Wei | other | 154,500 |
| May 9, 26 | Greenwood Luba | other | 22,000 |
| May 9, 26 | Lamb Lawrence | other | 54,000 |
| May 9, 26 | FAIRBAIRN EMILY | other | 22,000 |
| May 9, 26 | McCall Patrick | other | 56,250 |
| May 9, 26 | Rochlin Kate | other | 60,000 |
| May 9, 26 | Epperly Corinne | other | 22,000 |
| May 9, 26 | Brandt Peter C. | other | 22,000 |
| May 9, 26 | Graff Jeremy R. | other | 22,000 |
| Feb 4, 26 | Lamb Lawrence | other | 72,000 |
Our INAB Coverage
We haven't published any research on INAB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate INAB Report →